Ansun is currently enrolling eligible patients in STOP-PIV (DAS181-3-01), a Phase 3 study of DAS181 treatment of lower respiratory tract parainfluenza infection (PIV) in immunocompromised patients (ClinicalTrials.gov Identifier: NCT03808922).

Parainfluenza refers to a group of viruses called human parainfluenza viruses (HPIVs) that cause symptoms similar to the common cold.  Most healthy people infected with HPIV recover with little or no treatment.  However, adults and children with a weakened immune system are at risk for developing a life-threatening infection.

Currently, there is neither a vaccine to prevent nor a drug to treat HPIV infection.

STOP-PIV is enrolling patients in a Phase 3 multi-center trial evaluating our investigational drug candidate, DAS181, as a potential treatment option for lower respiratory tract infection (LRTI) due to a sialic-acid dependent respiratory virus such as parainfluenza (PIV) or influenza virus (IFV) in immunocompromised patients.

Data from the Phase 2 study revealed that if a patient meets criteria listed below, he/she may benefit clinically from receiving DAS181:

• are immunocompromised (have received a stem cell transplant, organ transplant, or chemotherapy).
• have a PIV in lower lung infection.
• are currently receiving supplemental oxygen to help with breathing.

For more information about the STOP-PIV Phase 3 trial (DAS181-3-01), please visit the STOP-PIV page at www.ClinicalTrials.gov.